HCW Biologics Statistics
Total Valuation
HCW Biologics has a market cap or net worth of $29.12 million. The enterprise value is $40.80 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, after market close.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HCW Biologics has 37.82 million shares outstanding. The number of shares has increased by 5.37% in one year.
| Current Share Class | 37.82M |
| Shares Outstanding | 37.82M |
| Shares Change (YoY) | +5.37% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 47.77% |
| Owned by Institutions (%) | 3.07% |
| Float | 17.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.33 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.09
| Current Ratio | 0.09 |
| Quick Ratio | 0.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -97.19 |
Financial Efficiency
Return on equity (ROE) is -537.24% and return on invested capital (ROIC) is -140.08%.
| Return on Equity (ROE) | -537.24% |
| Return on Assets (ROA) | -74.57% |
| Return on Capital (ROIC) | -140.08% |
| Revenue Per Employee | $77,689 |
| Profits Per Employee | -$829,579 |
| Employee Count | 45 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.36% in the last 52 weeks. The beta is 0.84, so HCW Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | -29.36% |
| 50-Day Moving Average | 0.53 |
| 200-Day Moving Average | 0.93 |
| Relative Strength Index (RSI) | 57.14 |
| Average Volume (20 Days) | 28,708,663 |
Short Selling Information
The latest short interest is 8,092, so 0.02% of the outstanding shares have been sold short.
| Short Interest | 8,092 |
| Short Previous Month | 24,886 |
| Short % of Shares Out | 0.02% |
| Short % of Float | 0.05% |
| Short Ratio (days to cover) | 0.28 |
Income Statement
In the last 12 months, HCW Biologics had revenue of $3.50 million and -$37.33 million in losses. Loss per share was -$0.99.
| Revenue | 3.50M |
| Gross Profit | -4.12M |
| Operating Income | -37.09M |
| Pretax Income | -27.39M |
| Net Income | -37.33M |
| EBITDA | -36.75M |
| EBIT | -37.09M |
| Loss Per Share | -$0.99 |
Full Income StatementBalance Sheet
The company has $998,221 in cash and $12.68 million in debt, giving a net cash position of -$11.68 million or -$0.31 per share.
| Cash & Cash Equivalents | 998,221 |
| Total Debt | 12.68M |
| Net Cash | -11.68M |
| Net Cash Per Share | -$0.31 |
| Equity (Book Value) | -9.97M |
| Book Value Per Share | -0.26 |
| Working Capital | -21.75M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | -117.76% |
| Operating Margin | -1,060.88% |
| Pretax Margin | -1,067.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -2,452.46% |